<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557527</url>
  </required_header>
  <id_info>
    <org_study_id>283518</org_study_id>
    <nct_id>NCT04557527</nct_id>
  </id_info>
  <brief_title>Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment</brief_title>
  <acronym>VIKING</acronym>
  <official_title>Suprachoroidal Visco-buckling for the Treatment of Rhegmatogenous Retinal Detachment: A Randomized, Controlled, Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norfolk and Norwich University Trust Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Thomas' Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sunderland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mid and South Essex NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares standard surgery for retinal detachment (RD) (vitrectomy, cryotherapy and&#xD;
      gas) with a surgical variation that replaces the intraocular gas tamponade with&#xD;
      suprachoroidal injection of viscoelastic underneath the break that caused the retinal&#xD;
      detachment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and the potential risks, the eligible patients who have&#xD;
      given written consent to the treatment will be randomized into treatment (vitrectomy, cryo&#xD;
      and gas) or control (viscobuckle vitrectomy) group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patient will be recruited into</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>randomisation software</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To establish if it is feasible to recruit, retain, and evaluate patients with RD into a larger randomised controlled trial of vitrectomy and suprachoroidal viscobuckle.</measure>
    <time_frame>2 years</time_frame>
    <description>feasibility trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To make a preliminary assessment of safety and efficacy of suprachoroidal viscobuckle.</measure>
    <time_frame>2 years</time_frame>
    <description>feasibility trial</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Retinal Detachment With Break</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pars plana vitrectomy, retinopexy with laser or cryotherapy, and intravitreal gas tamponade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pars plana vitrectomy, laser retinopexy, suprachoroidal viscobuckle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade</intervention_name>
    <description>Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)</intervention_name>
    <description>After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients requiring pars plana vitrectomy for the treatment of primary rhegmatogenous&#xD;
        retinal detachment (RD) caused by a single break, or multiple breaks within one clock hour.&#xD;
        The final determination of qualifying breaks is made at the time of surgery following&#xD;
        360-degree, internal, indented search using a wide-angle viewing system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to hyaluronate or. HEALON5® PRO OVD&#xD;
&#xD;
          -  Participation in another interventional study within 8 weeks of enrolment or planned&#xD;
             to occur during this study.&#xD;
&#xD;
          -  Bleeding disorders or the use of anticoagulants (such as warfarin, rivaroxaban) or&#xD;
             dual anti-platelet drugs such as aspirin with clopidogrel. Monotherapy with low dose&#xD;
             (≤100 mg) aspirin is permitted, and if clinically appropriate this should be stopped&#xD;
             prior to surgery and recommenced only after satisfactory day 1 post-operative review.&#xD;
&#xD;
          -  Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of&#xD;
             the trial.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, would prevent the&#xD;
             participant from granting informed consent or complying with the protocol, such as&#xD;
             dementia, mental illness, or serious systemic medical disease.&#xD;
&#xD;
        Study eye:&#xD;
&#xD;
          -  Presence of proliferative vitreoretinopathy (PVR) or any tractional RD&#xD;
&#xD;
          -  Previous vitreoretinal surgery, open-globe injury or endophthalmitis&#xD;
&#xD;
          -  Aphakia&#xD;
&#xD;
          -  Previous or current congenital cataract&#xD;
&#xD;
          -  Previous or current suprachoroidal haemorrhage&#xD;
&#xD;
          -  Congenital or acquired ocular, orbital or periocular abnormality that, in the opinion&#xD;
             of the attending vitreoretinal surgeon, would preclude the safe delivery of Healon 5&#xD;
             into the suprachoroidal space (detail the specific reason for exclusion in the source&#xD;
             documents)&#xD;
&#xD;
          -  Presence of other ocular co-morbidity that, in the opinion of the investigator, is&#xD;
             likely to prevent an accurate assessment of retinal attachment&#xD;
&#xD;
          -  Current intraocular inflammation other than mild cellular activity thought to be&#xD;
             secondary to RD&#xD;
&#xD;
          -  Current ocular or periocular infection other than blepharitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Riti Desai</last_name>
    <phone>020 3299 1297</phone>
    <phone_ext>31297</phone_ext>
    <email>ritidesai@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shohista Saidkasimova, FRCOphth</last_name>
    <phone>+44(0)1603288455</phone>
    <email>shohista.saidkasimova@nnuh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunderland Eye Infimary</name>
      <address>
        <city>Sunderland</city>
        <state>Tyne And Wear</state>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St. Thomas' Hospital NHS Foundatrion Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Alistair Laidlaw, MD, FRCOphth</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR47UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Shohista Saidkasimova, FRCOphth</last_name>
      <phone>44(0)1603288511</phone>
      <email>shohista.saidkasimova@nnuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Shohista Saidkasimova, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Southend</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Boden KT, Januschowski K, Szurman P. [Suprachoroidal Hydrogel Buckle - a New Minimal-Invasive Technique in Treatment of Rhegmatogenous Retinal Detachment]. Klin Monbl Augenheilkd. 2019 Mar;236(3):308-312. doi: 10.1055/s-0043-102947. Epub 2017 Apr 4. German.</citation>
    <PMID>28376555</PMID>
  </reference>
  <reference>
    <citation>El Rayes EN, Mikhail M, El Cheweiky H, Elsawah K, Maia A. SUPRACHOROIDAL BUCKLING FOR THE MANAGEMENT OF RHEGMATOGENOUS RETINAL DETACHMENTS SECONDARY TO PERIPHERAL RETINAL BREAKS. Retina. 2017 Apr;37(4):622-629. doi: 10.1097/IAE.0000000000001214.</citation>
    <PMID>27482642</PMID>
  </reference>
  <reference>
    <citation>Mikhail M, El-Rayes EN, Kojima K, Ajlan R, Rezende F. Catheter-guided suprachoroidal buckling of rhegmatogenous retinal detachments secondary to peripheral retinal breaks. Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):17-23. doi: 10.1007/s00417-016-3530-8. Epub 2016 Nov 16.</citation>
    <PMID>27853956</PMID>
  </reference>
  <reference>
    <citation>Mitry D, Awan MA, Borooah S, Siddiqui MA, Brogan K, Fleck BW, Wright A, Campbell H, Singh J, Charteris DG, Yorston D. Surgical outcome and risk stratification for primary retinal detachment repair: results from the Scottish Retinal Detachment study. Br J Ophthalmol. 2012 May;96(5):730-4. doi: 10.1136/bjophthalmol-2011-300581. Epub 2012 Jan 18.</citation>
    <PMID>22257789</PMID>
  </reference>
  <reference>
    <citation>Jackson TL, Donachie PH, Sallam A, Sparrow JM, Johnston RL. United Kingdom National Ophthalmology Database study of vitreoretinal surgery: report 3, retinal detachment. Ophthalmology. 2014 Mar;121(3):643-8. doi: 10.1016/j.ophtha.2013.07.015. Epub 2013 Aug 23.</citation>
    <PMID>23978624</PMID>
  </reference>
  <reference>
    <citation>Poole TA, Sudarsky RD. Suprachoroidal implantation for the treatment of retinal detachment. Ophthalmology. 1986 Nov;93(11):1408-12.</citation>
    <PMID>3808600</PMID>
  </reference>
  <reference>
    <citation>Mohamed YH, Ono K, Kinoshita H, Uematsu M, Tsuiki E, Fujikawa A, Kitaoka T. Success Rates of Vitrectomy in Treatment of Rhegmatogenous Retinal Detachment. J Ophthalmol. 2016;2016:2193518. doi: 10.1155/2016/2193518. Epub 2016 Jul 13.</citation>
    <PMID>27478632</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retinal detachment</keyword>
  <keyword>vitrectomy</keyword>
  <keyword>gas tamponnade</keyword>
  <keyword>suprachoroidal buckle</keyword>
  <keyword>viscobuckle</keyword>
  <keyword>postoperative recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

